FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 351:56-67 July 1, 2004 Number 1 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Alzheimer's disease is a progressive and fatal neurodegenerative disorder manifested by cognitive and memory deterioration, progressive impairment of activities of daily living, and a variety of neuropsychiatric symptoms and behavioral disturbances. Prevalence studies suggest that in 2000 the number of persons with Alzheimer's disease in the United States was 4.5 million.¹ The percentage of persons with Alzheimer's disease increases by a factor of two with approximately every five years of age, meaning that 1 percent of 60-year-olds and about 30 percent of 85-year-olds have the disease.² Without advances in therapy, the number of symptomatic cases in the United States is . . . [Full Text of this Article]

Diagnosis

Pathophysiology

Treatment

Antiamyloid Therapies

Neuroprotective Approaches

Antioxidants

Memantine

Antiinflammatory Agents

Hormone-Replacement Therapy

Cholinesterase Inhibitors

Other Treatments for Cognitive Deterioration

Management of Neuropsychiatric Symptoms and Behavioral Disturbances

Health Maintenance and General Medical Treatment

Alliance with Caregivers

Conclusions

Source Information

From the Departments of Neurology and Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles.

Address reprint requests to Dr. Cummings at Reed Neurological Research Center, UCLA, 710 Westwood Plaza, Box 951769, Los Angeles, CA 90095-1769, or at jcummings@mednet.ucla.edu.

Related Letters:

Drug Therapy in Alzheimer's Disease
de la Torre J., Aliev G., Perry G., Finucane T. E., Meyer M. A., Cummings J. L.
Extract | Full Text | PDF  
N Engl J Med 2004; 351:1911-1913, Oct 28, 2004. Correspondence

This article has been cited by other articles:

• Payot, I., Latour, J., Massoud, F., Kergoat, M.-J. (2007). Validation d'indicateurs de la prise en charge des atteintes des fonctions cognitives dans les unites d'evaluation geriatrique. cfp 53: 1944-1952 [Abstract] [Full Text]  
• Cummings, J. L., Doody, R., Clark, C. (2007). Disease-modifying therapies for Alzheimer disease: Challenges to early intervention. Neurology 69: 1622-1634 [Abstract] [Full Text]  
• Spalletta, G., Bernardini, S., Bellincampi, L., Federici, G., Trequattrini, A., Ciappi, F., Bria, P., Caltagirone, C., Bossu, P. (2007). Glutathione S-Transferase P1 and T1 Gene Polymorphisms Predict Longitudinal Course and Age at Onset of Alzheimer Disease. AJGP 15: 879-887 [Abstract] [Full Text]  
• Hutchinson, A D, Mathias, J L (2007). Neuropsychological deficits in frontotemporal dementia and Alzheimer's disease: a meta-analytic review. J. Neurol. Neurosurg. Psychiatry 78: 917-928 [Abstract] [Full Text]  
• Bossu, P., Ciaramella, A., Moro, M. L., Bellincampi, L., Bernardini, S., Federici, G., Trequattrini, A., Macciardi, F., Spoletini, I., Di Iulio, F., Caltagirone, C., Spalletta, G. (2007). Interleukin 18 gene polymorphisms predict risk and outcome of Alzheimer's disease. J. Neurol. Neurosurg. Psychiatry 78: 807-811 [Abstract] [Full Text]  
• Schott, J M (2007). A neurological MRI menagerie. PN 7: 186-190 [Full Text]  
• Wanaverbecq, N., Semyanov, A., Pavlov, I., Walker, M. C., Kullmann, D. M. (2007). Cholinergic Axons Modulate GABAergic Signaling among Hippocampal Interneurons via Postsynaptic {alpha}7 Nicotinic Receptors. J. Neurosci. 27: 5683-5693 [Abstract] [Full Text]  
• Juhn, P., Phillips, A., Buto, K. (2007). Balancing Modern Medical Benefits And Risks. Health Aff (Millwood) 26: 647-652 [Abstract] [Full Text]  
• Reed, B. R., Mungas, D. M., Kramer, J. H., Ellis, W., Vinters, H. V., Zarow, C., Jagust, W. J., Chui, H. C. (2007). Profiles of neuropsychological impairment in autopsy-defined Alzheimer's disease and cerebrovascular disease. Brain 130: 731-739 [Abstract] [Full Text]  
• Blaszczyk, A. T., Mathys, M. (2007). Treatment of Cognitive Decline and Psychiatric Disturbances Associated With Alzheimer's Dementia. Journal of Pharmacy Practice 20: 13-28 [Abstract]  
• Calderon-Garciduenas, L., Franco-Lira, M., Torres-Jardon, R., Henriquez-Roldan, C., Barragan-Mejia, G., Valencia-Salazar, G., Gonzalez-Maciel, A., Reynoso-Robles, R., Villarreal-Calderon, R., Reed, W. (2007). Pediatric Respiratory and Systemic Effects of Chronic Air Pollution Exposure: Nose, Lung, Heart, and Brain Pathology. Toxicol Pathol 35: 154-162 [Abstract]  
• Scarmeas, N., Stern, Y., Mayeux, R., Luchsinger, J. A. (2006). Mediterranean Diet, Alzheimer Disease, and Vascular Mediation. Arch Neurol 63: 1709-1717 [Abstract] [Full Text]  
• Klafki, H.-W., Staufenbiel, M., Kornhuber, J., Wiltfang, J. (2006). Therapeutic approaches to Alzheimer's disease. Brain 129: 2840-2855 [Abstract] [Full Text]  
• Clarke, R. (2006). Vitamin B12, folic acid, and the prevention of dementia.. NEJM 354: 2817-2819 [Full Text]  
• Unger, C., Svedberg, M. M., Yu, W.-F., Hedberg, M. M., Nordberg, A. (2006). Effect of Subchronic Treatment of Memantine, Galantamine, and Nicotine in the Brain of Tg2576 (APPswe) Transgenic Mice. J. Pharmacol. Exp. Ther. 317: 30-36 [Abstract] [Full Text]  
• Reitz, C., Luchsinger, J. A., Tang, M.-X., Manly, J., Mayeux, R. (2006). Stroke and memory performance in elderly persons without dementia.. Arch Neurol 63: 571-576 [Abstract] [Full Text]  
• Walker, D. G., Link, J., Lue, L.-F., Dalsing-Hernandez, J. E., Boyes, B. E. (2006). Gene expression changes by amyloid {beta} peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. J. Leukoc. Biol. 79: 596-610 [Abstract] [Full Text]  
• Kuriyama, S., Hozawa, A., Ohmori, K., Shimazu, T., Matsui, T., Ebihara, S., Awata, S., Nagatomi, R., Arai, H., Tsuji, I. (2006). Green tea consumption and cognitive function: a cross-sectional study from the Tsurugaya Project 1. Am. J. Clin. Nutr. 83: 355-361 [Abstract] [Full Text]  
• Csernansky, J. G., Wang, L., Miller, J. P., Galvin, J. E., Morris, J. C. (2005). Neuroanatomical Predictors of Response to Donepezil Therapy in Patients With Dementia. Arch Neurol 62: 1718-1722 [Abstract] [Full Text]  
• Rosenberg, R. N. (2005). Translational Research on the Way to Effective Therapy for Alzheimer Disease. Arch Gen Psychiatry 62: 1186-1192 [Abstract] [Full Text]  
• Feldman, H. H., Woodward, M. (2005). The staging and assessment of moderate to severe Alzheimer disease. Neurology 65: S10-S17 [Abstract] [Full Text]  
• Farlow, M. R. (2005). The search for disease modification in moderate to severe Alzheimer disease: A critical review of current evidence. Neurology 65: S25-S30 [Full Text]  
• Rutten, B. P.F., Van der Kolk, N. M., Schafer, S., van Zandvoort, M. A.M.J., Bayer, T. A., Steinbusch, H. W.M., Schmitz, C. (2005). Age-Related Loss of Synaptophysin Immunoreactive Presynaptic Boutons within the Hippocampus of APP751SL, PS1M146L, and APP751SL/PS1M146L Transgenic Mice. Am. J. Pathol. 167: 161-173 [Abstract] [Full Text]  
• Linnebur, S. A., Ruscin, J. M. (2005). Cholinesterase inhibitor use in geriatric outpatients with dementia. Am J Health Syst Pharm 62: 923-926 [Full Text]  
• Paganetti, P., Calanca, V., Galli, C., Stefani, M., Molinari, M. (2005). {beta}-site specific intrabodies to decrease and prevent generation of Alzheimer's A{beta} peptide. J. Cell Biol. 168: 863-868 [Abstract] [Full Text]  
• Budson, A. E., Price, B. H. (2005). Memory Dysfunction. NEJM 352: 692-699 [Full Text]  
• Press, D. Z. (2004). Parkinson's Disease Dementia -- A First Step?. NEJM 351: 2547-2549 [Full Text]  
• de la Torre, J., Aliev, G., Perry, G., Finucane, T. E., Meyer, M. A., Cummings, J. L. (2004). Drug Therapy in Alzheimer's Disease. NEJM 351: 1911-1913 [Full Text]